CDC Warns Multi-Drug Resistant Candida auris Superbug Cases Exceed 3,400 in 27 States

If you are healthy and going about your daily life, the latest public health alert regarding a drug-resistant superbug is not a reason to panic. The pathogen does not circulate in the community or pose a threat to the general public. However, if you have a vulnerable family member currently residing in a hospital, nursing home, or long-term care facility, the landscape of their care environment is actively changing.

The Centers for Disease Control and Prevention (CDC) has issued a warning regarding the rapid spread of Candida auris, a multidrug-resistant fungus. According to federal surveillance data released this week, more than 3,400 clinical cases have been reported across 27 states so far in 2026. The fungus, which can cause severe bloodstream infections, has become increasingly established in healthcare facilities across the country.[1][2]

The geographic footprint of the outbreak is expanding. California has reported the highest number of infections this year with 873 cases, followed closely by Texas with 433. Other states, including Michigan, Illinois, and Georgia, are also tracking hundreds of cases. The CDC notes that while the rate of increase has slowed slightly since 2022, the sheer volume of infections continues to climb annually, with 6,304 clinical cases recorded nationwide in 2024.[1][3]

Candida auris is a type of yeast that was first identified in 2009. Unlike common fungal infections, it is exceptionally resilient, capable of surviving for extended periods on hospital surfaces and shared medical equipment. It spreads primarily through direct contact with colonized patients or contaminated environments, making infection control in acute care settings incredibly difficult.[2]

The primary concern driving the CDC's alert is the pathogen's resistance to standard treatments. A significant percentage of C. auris isolates are resistant to fluconazole, a first-line antifungal medication, and some strains have evolved to evade all three major classes of antifungal drugs. For patients who are already severely ill, this lack of treatment options can be fatal, with researchers estimating mortality rates between 30% and 60% for those who develop invasive infections.[2]

The risk profile for C. auris is highly specific. The fungus preys on medically fragile individuals with weakened immune systems or those who require invasive medical devices such as breathing tubes, feeding tubes, and central venous catheters. Patients who experience frequent hospitalizations or reside in skilled nursing facilities are at the highest risk of exposure and subsequent infection.

Identifying an infection can be challenging because the symptoms—such as fever, chills, and low blood pressure—often mimic those of bacterial infections. Patients are typically treated with antibiotics first; when they fail to improve, physicians must pivot to testing for fungal pathogens. Healthcare providers can also screen asymptomatic patients using skin swabs to determine if they are colonized and capable of spreading the fungus to others.[2]

In response to the growing case counts, public health officials are urging healthcare facilities to implement rigorous infection prevention and control practices. This includes isolating infected patients in private rooms, enhancing environmental cleaning protocols, and adhering strictly to hand hygiene standards. For families of vulnerable patients, experts recommend maintaining open communication with care teams and advocating for proactive screening, particularly if a loved one is being transferred between medical facilities.[3]